Research programme: neuropsychotherapeutics - Acadia pharmaceuticals
Latest Information Update: 01 Mar 2024
At a glance
- Originator ACADIA Pharmaceuticals
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 22 Feb 2024 Preclinical trials in CNS disorders in USA (unspecified route) (Acadia pharmaceuticals pipeline, February 2024)